Hillsdale Investment Management’s AstraZeneca AZN Stock Holding History

Hillsdale Investment Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-50	Closed	-$5K	–	540
2020 Q4	$5K	Sell	50 -30	-38%	-$3.18K	﹤0.01%	541
2020 Q3	$9K	Buy	80 +35	+78%	+$3.89K	﹤0.01%	493
2020 Q2	$5K	Buy	+45	New	+$4.65K	﹤0.01%	500
2015 Q4	–	Sell	-150	Closed	-$10K	–	500
2015 Q3	$10K	Hold	150	–	–	﹤0.01%	453
2015 Q2	$10K	Hold	150	–	–	﹤0.01%	482
2015 Q1	$10K	Hold	150	–	–	﹤0.01%	484
2014 Q4	$11K	Hold	150	–	–	﹤0.01%	488
2014 Q3	$11K	Sell	150 -1,400	-90%	-$102K	﹤0.01%	483
2014 Q2	$115K	Hold	1,550	–	–	0.03%	374
2014 Q1	$101K	Hold	1,550	–	–	0.03%	374
2013 Q4	$92K	Sell	1,550 -9,720	-86%	-$528K	0.03%	387
2013 Q3	$585K	Sell	11,270 -250	-2%	-$12.6K	0.17%	77
2013 Q2	$545K	Buy	+11,520	New	+$587K	0.18%	75

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hillsdale Investment Management's AZN Position: Q1 2021 in Review

Hillsdale Investment Management sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 50 shares — an estimated $5K sold.

Hillsdale Investment Management first reported a position in AZN in Q2 2013 and held it in 13 quarters. The position peaked at $585K in Q3 2013. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

Hillsdale Investment Management reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
Hillsdale Investment Management sold 50 AstraZeneca shares in Q1 2021, an estimated $5K.
Hillsdale Investment Management first reported a position in AstraZeneca in Q2 2013 and held it in 13 quarters.
Hillsdale Investment Management's AstraZeneca position peaked at $585K in Q3 2013.
756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Hillsdale Investment Management's 13F filing for Q1 2021, filed 22 Apr 2021.